Johnson & Johnson profits rise

Johnson & Johnson reported excellent financial results for the third quarter of 2026, surpassing analysts' adjusted earnings expectations and increasing revenues to $25.4 billion. The company also reaffirmed its strategy to spin off its Orthopedics division, which includes joint replacement products, by mid-2027, in order to enhance shareholder value. The results showed a 7.7% increase in pharmaceutical sales to $16.76 billion, with strong growth in Trimbovia sales, up 68%, while the Medical Technology segment experienced growth that was below expectations. Johnson & Johnson raised its annual sales forecast to approximately $101.2 billion and earnings per share to $11.10, despite a 2% decline in stocks before trading opened, due to concerns over the performance of the Technology sector and some quarterly results.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل